Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 7Thoracic 3Gynecologic 3Dermatologic 3Sarcoma 2Genitourinary 2Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Gliosarcoma 7Glioblastoma 7Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Lymphoma 6Dendritic Cell Sarcoma, Interdigitating 6Brain Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Central Nervous System Neoplasms 5Burkitt Lymphoma 5Astrocytoma 5Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4Leukemia 4Hodgkin Disease 4Ovarian Neoplasms 3Oligodendroglioma 3Neuroblastoma 3Myelodysplastic Syndromes 3Triple Negative Breast Neoplasms 2Sarcoma, Synovial 2Neuroectodermal Tumors, Primitive 2Neoplasms, Plasma Cell 2

Interventions

pembrolizumab 7Cyclophosphamide 6Nivolumab 4fludarabine 3spartalizumab 2aldesleukin 2Trastuzumab 2Standard of Care 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Irinotecan 2Ipilimumab 2Gemcitabine 2zanidatamab 1vocimagene amiretrorepvec 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tinostamustine 1talazoparib 1sarilumab 1sargramostim 1regorafenib 1pexidartinib 1pertuzumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × aldesleukin × Sarcoma × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡